These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 8105072)

  • 1. Effect of intravenous immunoglobulin (IVIG) on CD4+ lymphocyte decline in HIV-infected children in a clinical trial of IVIG infection prophylaxis. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
    Mofenson LM; Bethel J; Moye J; Flyer P; Nugent R
    J Acquir Immune Defic Syndr (1988); 1993 Oct; 6(10):1103-13. PubMed ID: 8105072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prophylactic intravenous immunoglobulin in HIV-infected children with CD4+ counts of 0.20 x 10(9)/L or more. Effect on viral, opportunistic, and bacterial infections. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
    Mofenson LM; Moye J; Bethel J; Hirschhorn R; Jordan C; Nugent R
    JAMA; 1992 Jul 22-29; 268(4):483-8. PubMed ID: 1352363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus-infected children. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
    Mofenson LM; Moye J; Korelitz J; Bethel J; Hirschhorn R; Nugent R
    Pediatr Infect Dis J; 1994 Jun; 13(6):477-84. PubMed ID: 8078734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized controlled trial of short-term withdrawal of i.v. immunoglobulin therapy for selected children with human immunodeficiency virus infection.
    Grisaru-Soen G; Lau W; Arneson C; Louch D; Bitnun A; Stephens D; Read SE; King SM
    Pediatr Int; 2007 Dec; 49(6):972-7. PubMed ID: 18045306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection.
    National Institute of Child Health and Human Developments Intravenous Immunoglobulin Study Group
    N Engl J Med; 1991 Jul; 325(2):73-80. PubMed ID: 1675763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group.
    Spector SA; Gelber RD; McGrath N; Wara D; Barzilai A; Abrams E; Bryson YJ; Dankner WM; Livingston RA; Connor EM
    N Engl J Med; 1994 Nov; 331(18):1181-7. PubMed ID: 7935655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.
    Fischl MA; Richman DD; Hansen N; Collier AC; Carey JT; Para MF; Hardy WD; Dolin R; Powderly WG; Allan JD
    Ann Intern Med; 1990 May; 112(10):727-37. PubMed ID: 1970466
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous immune globulin for the prevention of infections in children with symptomatic human immunodeficiency virus infection.
    Mofenson LM; Moye J
    Pediatr Res; 1993 Jan; 33(1 Suppl):S80-7; discussion S87-9. PubMed ID: 8433880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined therapy in human immunodeficiency virus-infected children--a 4-year experience.
    Güngör T; Funk M; Linde R; Kynast I; Allendorf A; Lotz C; Ehrenforth S; Hofmann D; Kornhuber B; Kreuz W
    Eur J Pediatr; 1993 Aug; 152(8):650-4. PubMed ID: 8104791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics of acute pneumonia in human immunodeficiency virus-infected children and association with long term mortality risk. National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group.
    Mofenson LM; Yogev R; Korelitz J; Bethel J; Krasinski K; Moye J; Nugent R; Rigau-Perez JG
    Pediatr Infect Dis J; 1998 Oct; 17(10):872-80. PubMed ID: 9802627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunologic targets of HIV infection: T cells. NICHD IVIG Clinical Trial Group, and the NHLBI P2C2 Pediatric Pulmonary and Cardiac Complications of HIV Infection Study Group.
    Shearer WT; Rosenblatt HM; Schluchter MD; Mofenson LM; Denny TN
    Ann N Y Acad Sci; 1993 Oct; 693():35-51. PubMed ID: 7903519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zidovudine in persons with asymptomatic HIV infection and CD4+ cell counts greater than 400 per cubic millimeter. The European-Australian Collaborative Group.
    Cooper DA; Gatell JM; Kroon S; Clumeck N; Millard J; Goebel FD; Bruun JN; Stingl G; Melville RL; González-Lahoz J
    N Engl J Med; 1993 Jul; 329(5):297-303. PubMed ID: 8100611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravenous immune globulin for prevention of bacterial infections in pediatric AIDS patients.
    Crow ME
    Am J Health Syst Pharm; 1995 Apr; 52(8):803-11. PubMed ID: 7634115
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for reducing perinatal HIV transmission from HIV-infected women with advanced disease: results of Pediatric AIDS Clinical Trials Group protocol 185.
    Stiehm ER; Lambert JS; Mofenson LM; Bethel J; Whitehouse J; Nugent R; Moye J; Glenn Fowler M; Mathieson BJ; Reichelderfer P; Nemo GJ; Korelitz J; Meyer WA; Sapan CV; Jimenez E; Gandia J; Scott G; O'Sullivan MJ; Kovacs A; Stek A; Shearer WT; Hammill H
    J Infect Dis; 1999 Mar; 179(3):567-75. PubMed ID: 9952362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of thymopentin in zidovudine (AZT)-treated asymptomatic HIV-infected subjects with 200-500 CD4 cells/mm3: a double-blind placebo-controlled trial.
    Goldstein G; Conant MA; Beall G; Grossman HA; Galpin JE; Blick G; Calabrese LH; Hirsch RL; Fisher A; Stampone P
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Mar; 8(3):279-88. PubMed ID: 7859140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party.
    Bartlett JA; Benoit SL; Johnson VA; Quinn JB; Sepulveda GE; Ehmann WC; Tsoukas C; Fallon MA; Self PL; Rubin M
    Ann Intern Med; 1996 Aug; 125(3):161-72. PubMed ID: 8686973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.
    Volberding PA; Lagakos SW; Koch MA; Pettinelli C; Myers MW; Booth DK; Balfour HH; Reichman RC; Bartlett JA; Hirsch MS
    N Engl J Med; 1990 Apr; 322(14):941-9. PubMed ID: 1969115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.
    Verweel G; van Rossum AM; Hartwig NG; Wolfs TF; Scherpbier HJ; de Groot R
    Pediatrics; 2002 Feb; 109(2):E25. PubMed ID: 11826235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized double-blind trial of the addition of lamivudine or matching placebo to current nucleoside analogue reverse transcriptase inhibitor therapy in HIV-infected children: the PENTA-4 trial. Paediatric European Network for Treatment of AIDS.
    AIDS; 1998 Oct; 12(14):F151-60. PubMed ID: 9792371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Zidovudine twice daily in asymptomatic subjects with HIV infection and a high risk of progression to AIDS: a randomized, double-blind placebo-controlled study. The European-Australian Collaborative Group (Study 017).
    Mulder JW; Cooper DA; Mathiesen L; Sandström E; Clumeck N; Gatell JM; French M; Donovan B; Gray F; Yeo JM
    AIDS; 1994 Mar; 8(3):313-21. PubMed ID: 7913326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.